fulvestrant

Known as: 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol, 7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol, fulvestrant [Chemical/Ingredient] 
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast… (More)
  • figure 1
  • figure 3
  • figure 4
  • table 1
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The development of targeted therapies for antiestrogen-resistant breast cancer requires a detailed understanding of its molecular… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE To evaluate the efficacy and tolerability of fulvestrant (Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE), a… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of… (More)
Is this relevant?